急性リンパ芽球性白血病患者の治療におけるドナー幹細胞移植を伴うまたは伴わない併用化学療法
フィラデルフィア (Ph) 染色体陽性および/または BCR-ABL 陽性の急性リンパ芽球性白血病 (ALL) 患者における同種幹細胞移植の有無にかかわらず、Hyper-CVAD とダサチニブ (NSC-732517) の組み合わせの第 II 相試験 (BMT 試験)
This phase II trial is studying the side effects of giving combination chemotherapy together with or without donor stem cell transplant and to see how well it works in treating patients with acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Giving chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect).
調査の概要
状態
条件
介入・治療
- 他の:Laboratory Biomarker Analysis
- 薬:Cyclophosphamide
- 薬:Doxorubicin Hydrochloride
- 薬:Prednisone
- 薬:Dexamethasone
- 薬:Vincristine Sulfate
- 薬:Etoposide
- 薬:Methylprednisolone
- 生物学的:Filgrastim
- 薬:Dasatinib
- 薬:Leucovorin Calcium
- 薬:Sirolimus
- 放射線:Total-Body Irradiation
- 薬:Tacrolimus
- 薬:Cytarabine
- 薬:Methotrexate
- 手順:Allogeneic Hematopoietic Stem Cell Transplantation
- 手順:Peripheral Blood Stem Cell Transplantation
詳細な説明
PRIMARY OBJECTIVES:
I. To test whether the relapse-free survival after allogeneic stem cell transplantation among Philadelphia chromosome positive and/or breakpoint cluster region (BCR)/Abelson murine leukemia viral oncogene (ABL) positive acute lymphoblastic leukemia (ALL) patients given an intensive short-term chemotherapy regimen of fractionated cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, and dexamethasone (hyper-CVAD) in combination with the tyrosine kinase inhibitor dasatinib is sufficiently high to warrant further investigation.
SECONDARY OBJECTIVES:
I. To test whether the continuous complete remission rate for previously untreated Philadelphia chromosome positive and/or BCR/ABL positive acute lymphoblastic leukemia (ALL) patients given an intensive short-term chemotherapy regimen of hyper-CVAD in combination with the tyrosine kinase inhibitor dasatinib is sufficiently high to warrant phase III investigation.
II. To investigate in a preliminary manner the relative effectiveness of minimal residual disease (MRD) detection using real-time quantitative polymerase chain reaction (PCR) for BCR/ABL versus flow cytometry to predict the outcome of patients treated by the hyper-CVAD + dasatinib regimen and/or allogeneic stem cell transplant.
TERTIARY OBJECTIVES:
I. To estimate the frequency and severity of toxicities of the intensive short-term chemotherapy regimen in these patients.
II. To estimate the overall survival of all patients on this study.
OUTLINE:
INDUCTION/CONSOLIDATION THERAPY: All patients receive both of the following regimens in alternating courses:
COURSES 1, 3, 5, 7 or 3, 5, 7, 9: Patients receive cyclophosphamide intravenously (IV) over 3 hours twice daily (BID) on days 1-3; doxorubicin hydrochloride IV over 24 hours on day 4; vincristine sulfate IV over 30 minutes on days 4 and 11; dexamethasone IV or orally (PO) once daily (QD) on days 1-4 and 11-14; dasatinib PO QD on days 1-14; cytarabine intrathecally (IT) on day 7; methotrexate IT on day 2; and filgrastim (G-CSF) subcutaneously (SC) QD or BID.
COURSES 2, 4, 6, 8: Patients receive high-dose methotrexate IV over 24 hours on day 1; methylprednisolone IV over 30 minutes BID on days 1-3; dasatinib PO QD on days 1-14; high-dose cytarabine IV over 2 hours BID on days 2-3; leucovorin calcium IV on days 2 or 3; methotrexate IT on day 2; cytarabine IT on day 7; and G-CSF SC QD or BID.
Treatment repeats every 14-21 days for 8 courses in the absence of disease progression, unacceptable toxicity, or if patient achieves complete remission (CR) or complete remission with incomplete platelet recovery (CRi).
MAINTENANCE THERAPY*: Patients receive vincristine sulfate IV over 30 minutes on day 1, prednisone PO QD on days 1-5, and dasatinib PO QD on days 1-28.
Treatment repeats every month for 24 courses in the absence of disease progression or unacceptable toxicity or until the transplant is ready.
INTENSIFICATION: For courses 6 and 13, patients receive cyclophosphamide IV over 3 hours BID on days 1-3; doxorubicin hydrochloride IV over 24 hours on day 4; vincristine sulfate IV over 30 minutes on days 4 and 11; dexamethasone IV or PO QD on days 1-4 and 11-14; dasatinib PO QD on days 1-14; and G-CSF SC QD or BID.
NOTE: *Only if transplantation is not ready after induction/consolidation therapy or patients are not undergoing a transplant.
ALLOGENEIC STEM CELL TRANSPLANTATION (FOR PATIENTS ACHIEVING CR OR CRi):
CONDITIONING REGIMEN: Patients receive 1 of the following regimens:
REGIMEN A: Patients receive total-body irradiation (TBI) QD on days -7 to -4 and cyclophosphamide IV on days -3 and -2.
REGIMEN B: Patients receive TBI BID on days -6 to -4 and cyclophosphamide IV on days -3 and -2.
REGIMEN C: Patients receive cyclophosphamide IV on days -7 and -6 and TBI QD on days -4 to -1.
REGIMEN D: Patients receive cyclophosphamide IV on days -6 and -5 and TBI BID on days -3 to -1.
REGIMEN E: Patients receive TBI QD on days -7 to -4 and etoposide IV on day -3.
REGIMEN F: Patients receive TBI BID on days -6 to -4 and etoposide IV on day -3.
ALLOGENEIC STEM CALL TRANSPLANTATION: Patients undergo allogeneic stem cell transplantation on day 0.
GRAFT-VS-HOST DISEASE (GVHD) PROPHYLAXIS: Patients receive 1 of the following regimens:
REGIMEN A: Patients receive sirolimus PO and tacrolimus IV continuously (changing to PO BID) beginning on day -3 and continuing for 6 months.
REGIMEN B: Patients receive tacrolimus IV continuously (changing to PO BID) and continuing for 6 months, and methotrexate IV on days 1, 3, 6, and 11.
SINGLE-AGENT THERAPY: After completion of maintenance therapy or beginning on day 100 post-transplantation, patients receive dasatinib PO QD for up to 5 years.
After completion of study therapy, patients are followed every 6 months for up to 5 years.
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Arizona
-
Tucson、Arizona、アメリカ、85719
- Banner University Medical Center - Tucson
-
Tucson、Arizona、アメリカ、85719
- University of Arizona Cancer Center-North Campus
-
-
California
-
Duarte、California、アメリカ、91010
- City of Hope Comprehensive Cancer Center
-
Palo Alto、California、アメリカ、94304
- Stanford Cancer Institute Palo Alto
-
Sacramento、California、アメリカ、95817
- University of California Davis Comprehensive Cancer Center
-
-
Florida
-
Gainesville、Florida、アメリカ、32610
- UF Health Cancer Institute - Gainesville
-
Orlando、Florida、アメリカ、32803
- AdventHealth Orlando
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30322
- Emory University Hospital/Winship Cancer Institute
-
-
Illinois
-
Berwyn、Illinois、アメリカ、60402
- MacNeal Hospital and Cancer Center
-
Chicago、Illinois、アメリカ、60611
- Northwestern University
-
Chicago、Illinois、アメリカ、60637
- University of Chicago Comprehensive Cancer Center
-
Chicago、Illinois、アメリカ、60611
- Hematology and Oncology Associates
-
Highland Park、Illinois、アメリカ、60035
- Hematology Oncology Associates of Illinois-Highland Park
-
Kankakee、Illinois、アメリカ、60901
- Presence Saint Mary's Hospital
-
Libertyville、Illinois、アメリカ、60048
- AMG Libertyville - Oncology
-
Maywood、Illinois、アメリカ、60153
- Loyola University Medical Center
-
Naperville、Illinois、アメリカ、60563
- DuPage Medical Group-Ogden
-
Niles、Illinois、アメリカ、60714
- Illinois Cancer Specialists-Niles
-
Skokie、Illinois、アメリカ、60076
- Hematology Oncology Associates of Illinois - Skokie
-
Springfield、Illinois、アメリカ、62781
- Springfield Memorial Hospital
-
-
Indiana
-
Beech Grove、Indiana、アメリカ、46107
- Franciscan Saint Francis Health-Beech Grove
-
Fort Wayne、Indiana、アメリカ、46845
- Fort Wayne Medical Oncology and Hematology Inc-Parkview
-
Richmond、Indiana、アメリカ、47374
- Reid Health
-
-
Iowa
-
Sioux City、Iowa、アメリカ、51101
- Siouxland Regional Cancer Center
-
Sioux City、Iowa、アメリカ、51102
- Mercy Medical Center-Sioux City
-
Sioux City、Iowa、アメリカ、51104
- Saint Luke's Regional Medical Center
-
-
Kansas
-
Chanute、Kansas、アメリカ、66720
- Cancer Center of Kansas - Chanute
-
Dodge City、Kansas、アメリカ、67801
- Cancer Center of Kansas - Dodge City
-
El Dorado、Kansas、アメリカ、67042
- Cancer Center of Kansas - El Dorado
-
Fort Scott、Kansas、アメリカ、66701
- Cancer Center of Kansas - Fort Scott
-
Hays、Kansas、アメリカ、67601
- HaysMed
-
Hutchinson、Kansas、アメリカ、67502
- Hutchinson Regional Medical Center
-
Independence、Kansas、アメリカ、67301
- Cancer Center of Kansas-Independence
-
Kansas City、Kansas、アメリカ、66160
- University of Kansas Cancer Center
-
Kansas City、Kansas、アメリカ、66112
- University of Kansas Cancer Center-West
-
Kingman、Kansas、アメリカ、67068
- Cancer Center of Kansas-Kingman
-
Lawrence、Kansas、アメリカ、66044
- Lawrence Memorial Hospital
-
Liberal、Kansas、アメリカ、67905
- Cancer Center of Kansas-Liberal
-
Liberal、Kansas、アメリカ、67901
- Southwest Medical Center
-
McPherson、Kansas、アメリカ、67460
- Cancer Center of Kansas - McPherson
-
Newton、Kansas、アメリカ、67114
- Cancer Center of Kansas - Newton
-
Overland Park、Kansas、アメリカ、66210
- University of Kansas Cancer Center-Overland Park
-
Parsons、Kansas、アメリカ、67357
- Cancer Center of Kansas - Parsons
-
Pittsburg、Kansas、アメリカ、66762
- Mercy Hospital Pittsburg
-
Pratt、Kansas、アメリカ、67124
- Cancer Center of Kansas - Pratt
-
Salina、Kansas、アメリカ、67401
- Salina Regional Health Center
-
Salina、Kansas、アメリカ、67401
- Cancer Center of Kansas - Salina
-
Topeka、Kansas、アメリカ、66606
- University of Kansas Health System Saint Francis Campus
-
Wellington、Kansas、アメリカ、67152
- Cancer Center of Kansas - Wellington
-
Wichita、Kansas、アメリカ、67214
- Ascension Via Christi Hospitals Wichita
-
Wichita、Kansas、アメリカ、67208
- Cancer Center of Kansas-Wichita Medical Arts Tower
-
Wichita、Kansas、アメリカ、67214
- Cancer Center of Kansas - Wichita
-
Wichita、Kansas、アメリカ、67208
- Associates In Womens Health
-
Wichita、Kansas、アメリカ、67214
- Wichita NCI Community Oncology Research Program
-
Wichita、Kansas、アメリカ、67214
- Wesley Medical Center
-
Winfield、Kansas、アメリカ、67156
- Cancer Center of Kansas - Winfield
-
-
Kentucky
-
Lexington、Kentucky、アメリカ、40536
- University of Kentucky/Markey Cancer Center
-
-
Louisiana
-
Baton Rouge、Louisiana、アメリカ、70809
- Hematology/Oncology Clinic PLLC
-
New Orleans、Louisiana、アメリカ、70112
- Tulane University School of Medicine
-
Shreveport、Louisiana、アメリカ、71103
- LSU Health Sciences Center at Shreveport
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Baltimore、Maryland、アメリカ、21201
- University of Maryland/Greenebaum Cancer Center
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48109
- University of Michigan Rogel Cancer Center
-
Battle Creek、Michigan、アメリカ、49017
- Bronson Battle Creek
-
Big Rapids、Michigan、アメリカ、49307
- Spectrum Health Big Rapids Hospital
-
Detroit、Michigan、アメリカ、48201
- Wayne State University/Karmanos Cancer Institute
-
Grand Rapids、Michigan、アメリカ、49503
- Cancer Research Consortium of West Michigan NCORP
-
Grand Rapids、Michigan、アメリカ、49503
- Trinity Health Grand Rapids Hospital
-
Grand Rapids、Michigan、アメリカ、49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Muskegon、Michigan、アメリカ、49444
- Trinity Health Muskegon Hospital
-
Traverse City、Michigan、アメリカ、49684
- Munson Medical Center
-
Wyoming、Michigan、アメリカ、49519
- University of Michigan Health - West
-
-
Minnesota
-
Rochester、Minnesota、アメリカ、55905
- Mayo Clinic in Rochester
-
-
Missouri
-
Kansas City、Missouri、アメリカ、64154
- University of Kansas Cancer Center - North
-
Kansas City、Missouri、アメリカ、64131
- The University of Kansas Cancer Center-South
-
Kansas City、Missouri、アメリカ、64108
- University Health Truman Medical Center
-
Lee's Summit、Missouri、アメリカ、64064
- University of Kansas Cancer Center - Lee's Summit
-
St Louis、Missouri、アメリカ、63110
- Washington University School of Medicine
-
St Louis、Missouri、アメリカ、63104
- SSM Health Saint Louis University Hospital
-
-
Montana
-
Billings、Montana、アメリカ、59101
- Billings Clinic Cancer Center
-
Billings、Montana、アメリカ、59101
- Saint Vincent Healthcare
-
Billings、Montana、アメリカ、59102
- Montana Cancer Consortium NCORP
-
Billings、Montana、アメリカ、59102
- Saint Vincent Frontier Cancer Center
-
Bozeman、Montana、アメリカ、59715
- Bozeman Health Deaconess Hospital
-
Butte、Montana、アメリカ、59701
- Saint James Community Hospital and Cancer Treatment Center
-
Great Falls、Montana、アメリカ、59405
- Great Falls Clinic
-
Great Falls、Montana、アメリカ、59405
- Benefis Sletten Cancer Institute
-
Helena、Montana、アメリカ、59601
- Saint Peter's Community Hospital
-
Kalispell、Montana、アメリカ、59901
- Glacier Oncology PLLC
-
Kalispell、Montana、アメリカ、59901
- Logan Health Medical Center
-
Missoula、Montana、アメリカ、59802
- Saint Patrick Hospital - Community Hospital
-
Missoula、Montana、アメリカ、59802
- Montana Cancer Specialists
-
-
New York
-
Buffalo、New York、アメリカ、14263
- Roswell Park Cancer Institute
-
Rochester、New York、アメリカ、14642
- University of Rochester
-
The Bronx、New York、アメリカ、10467
- Montefiore Medical Center - Moses Campus
-
The Bronx、New York、アメリカ、10461
- Montefiore Medical Center-Weiler Hospital
-
-
North Carolina
-
Chapel Hill、North Carolina、アメリカ、27599
- UNC Lineberger Comprehensive Cancer Center
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45236
- The Jewish Hospital
-
Cleveland、Ohio、アメリカ、44106
- Case Western Reserve University
-
Cleveland、Ohio、アメリカ、44195
- Cleveland Clinic Foundation
-
Dayton、Ohio、アメリカ、45406
- Good Samaritan Hospital - Dayton
-
Dayton、Ohio、アメリカ、45409
- Miami Valley Hospital
-
Dayton、Ohio、アメリカ、45415
- Miami Valley Hospital North
-
Dayton、Ohio、アメリカ、45405
- Grandview Hospital
-
Dayton、Ohio、アメリカ、45459
- Dayton NCI Community Oncology Research Program
-
Findlay、Ohio、アメリカ、45840
- Blanchard Valley Hospital
-
Franklin、Ohio、アメリカ、45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Greenville、Ohio、アメリカ、45331
- Wayne Hospital
-
Kettering、Ohio、アメリカ、45429
- Kettering Medical Center
-
Lima、Ohio、アメリカ、45801
- Saint Rita's Medical Center
-
Troy、Ohio、アメリカ、45373
- Upper Valley Medical Center
-
Wilmington、Ohio、アメリカ、45177
- Clinton Memorial Hospital/Foster J Boyd Regional Cancer Center
-
Xenia、Ohio、アメリカ、45385
- Greene Memorial Hospital
-
-
Oklahoma
-
Oklahoma City、Oklahoma、アメリカ、73104
- University of Oklahoma Health Sciences Center
-
-
Pennsylvania
-
Hershey、Pennsylvania、アメリカ、17033-0850
- Penn State Milton S Hershey Medical Center
-
Lewistown、Pennsylvania、アメリカ、17044
- Lewistown Hospital
-
Philadelphia、Pennsylvania、アメリカ、19104
- University of Pennsylvania/Abramson Cancer Center
-
State College、Pennsylvania、アメリカ、16803
- Mount Nittany Medical Center
-
-
South Carolina
-
Charleston、South Carolina、アメリカ、29425
- Medical University of South Carolina
-
-
South Dakota
-
Sioux Falls、South Dakota、アメリカ、57105
- Avera Cancer Institute
-
Sioux Falls、South Dakota、アメリカ、57117-5045
- Avera McKennan Hospital and University Health Center
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37232
- Vanderbilt University/Ingram Cancer Center
-
-
Texas
-
Dallas、Texas、アメリカ、75246
- Baylor University Medical Center
-
Houston、Texas、アメリカ、77030
- UT MD Anderson Cancer Center
-
-
Utah
-
American Fork、Utah、アメリカ、84003
- American Fork Hospital / Huntsman Intermountain Cancer Center
-
Cedar City、Utah、アメリカ、84720
- Sandra L Maxwell Cancer Center
-
Logan、Utah、アメリカ、84321
- Logan Regional Hospital
-
Murray、Utah、アメリカ、84107
- Intermountain Medical Center
-
Ogden、Utah、アメリカ、84403
- McKay-Dee Hospital Center
-
Provo、Utah、アメリカ、84604
- Utah Valley Regional Medical Center
-
Salt Lake City、Utah、アメリカ、84112
- Huntsman Cancer Institute/University of Utah
-
Salt Lake City、Utah、アメリカ、84106
- Utah Cancer Specialists-Salt Lake City
-
Salt Lake City、Utah、アメリカ、84143
- LDS Hospital
-
St. George、Utah、アメリカ、84770
- Saint George Regional Medical Center
-
-
Washington
-
Anacortes、Washington、アメリカ、98221
- Cancer Care Center at Island Hospital
-
Bellingham、Washington、アメリカ、98225
- PeaceHealth Saint Joseph Medical Center
-
Burien、Washington、アメリカ、98166
- Saint Anne Hospital
-
Edmonds、Washington、アメリカ、98026
- Swedish Cancer Institute-Edmonds
-
Issaquah、Washington、アメリカ、98029
- Swedish Cancer Institute-Issaquah
-
Kennewick、Washington、アメリカ、99336
- Kadlec Clinic Hematology and Oncology
-
Mount Vernon、Washington、アメリカ、98274
- Skagit Valley Hospital
-
Poulsbo、Washington、アメリカ、98370
- Harrison HealthPartners Hematology and Oncology-Poulsbo
-
Seattle、Washington、アメリカ、98104
- Harborview Medical Center
-
Seattle、Washington、アメリカ、98122
- Swedish Medical Center-First Hill
-
Seattle、Washington、アメリカ、98195
- University of Washington Medical Center - Montlake
-
Seattle、Washington、アメリカ、98112
- Kaiser Permanente Washington
-
Seattle、Washington、アメリカ、98104
- Minor and James Medical PLLC
-
Seattle、Washington、アメリカ、98109
- Fred Hutchinson Cancer Center
-
Sedro-Woolley、Washington、アメリカ、98284
- PeaceHealth United General Medical Center
-
Silverdale、Washington、アメリカ、98383
- Saint Joseph Medical Center Hematology and Oncology - Silverdale
-
Spokane、Washington、アメリカ、99218
- Evergreen Hematology and Oncology PS
-
Spokane、Washington、アメリカ、99202
- Cancer Care Northwest - Spokane South
-
Wenatchee、Washington、アメリカ、98801
- Wenatchee Valley Hospital and Clinics
-
-
West Virginia
-
Morgantown、West Virginia、アメリカ、26506
- West Virginia University Healthcare
-
-
Wisconsin
-
Milwaukee、Wisconsin、アメリカ、53226
- Medical College of Wisconsin
-
-
Wyoming
-
Casper、Wyoming、アメリカ、82609
- Rocky Mountain Oncology
-
Sheridan、Wyoming、アメリカ、82801
- Welch Cancer Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
INDUCTION/CONSOLIDATION REGISTRATION:
-
Patients must have a morphologic diagnosis of acute lymphoblastic leukemia (ALL), with evidence of ALL involvement in bone marrow and/or blood; patients with only extramedullary disease in the absence of bone marrow or blood involvement are not eligible; patients with M0 acute myeloid leukemia (AML) or mixed lineage leukemia are not eligible for this study; patients with L3 (Burkitts) are also not eligible
- For ALL in marrow or peripheral blood, immunophenotyping of the blood or marrow lymphoblasts must be performed to determine lineage (B cell, T-cell, or mixed B/T cell); NOTE: appropriate marker studies including cluster of differentiation (CD)19 (B cell), CD10, CD5, and CD7 (T cell) must be performed; co-expression of myeloid antigens (CD13 and CD33) will not exclude patients; if possible, the lineage specific markers cytoplasmic CD22 or CD79a (B cells), cytoplasmic CD3 (T cells) and cytoplasmic myeloperoxidase (MPO) (myeloid cells) must be determined
-
Patients may have received no more than one course of remission induction therapy for ALL; patients who have received any post-remission therapy for ALL or who have relapsed from complete remission are not eligible; (patients with previously untreated ALL can be eligible, and patients who have received one course of remission induction therapy for ALL can be eligible, regardless of their response to therapy); patients may have received no more than 14 days of tyrosine kinase inhibitor therapy prior to registration; any prior induction chemotherapy must have been completed no more than 28 days prior to registration
- NOTE: If the patient has been initiated on the protocol defined regimen (i.e. the hyper-CVAD regimen without a tyrosine kinase inhibitor) before the Philadelphia chromosome (Ph)/BCR-ABL status was known, the patient may be registered on the protocol and start dasatinib; in this first course, dasatinib will be administered up to day 14 (i.e. if the patient is registered on day 5 and starts therapy on day 6, only 8 days of dasatinib will be administered and dasatinib will be completed on day 14)
-
For patients who have received any prior therapy that was NOT remission induction therapy, one of the following must be true:
- At least 6 weeks must have elapsed since any monoclonal antibodies were given, at least 7 days must have elapsed since any other treatment was given, and all toxicities of the remission induction therapy must have resolved to grade =< 2
- The patient must have rapidly progressive disease (per institutional guidelines)
-
For previously treated patients, the study chair must be contacted before registration, in order to determine the regimen to be given in the first course of induction/consolidation therapy, based on prior therapy
-
Patients must be Philadelphia (Ph) positive and/or BCR/ABL positive as confirmed by standard cytogenetics, fluorescent in situ hybridization (FISH), and/or polymerase chain reaction (PCR) testing performed by local laboratory; NOTE: samples will be submitted centrally for verification of results
-
Patients must have a bilirubin =< 3.0 x institutional upper limit of normal (IULN) within 14 days prior to registration
-
Patients must have serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 3.0 x IULN and/or serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 3.0 x IULN within 14 days prior to registration; if both tests are done then both values must be =< 3.0 x IULN
-
Patients must have a serum creatinine =< 3.0 x IULN within 14 days prior to registration
-
Patients must not have active pericardial effusion, ascites, or pleural effusion of any grade; exception: if the effusion is suspected to be related to the leukemia, the patient may have pericardial effusion of =< grade 2 or pleural effusion =< grade 1
-
Patients may not have any clinically significant cardiovascular disease including the following:
- Myocardial infarction or ventricular tachyarrhythmia within 6 months
- Prolonged corrected QT (QTc) >= 480 msec (Fridericia correction)
- Ejection fraction less than institutional normal
- Major conduction abnormality (unless a cardiac pacemaker is present)
- Patients with any cardiopulmonary symptoms of unknown cause (e.g. shortness of breath, chest pain, etc.) should be evaluated by a baseline echocardiogram with or without stress test as needed in addition to electrocardiogram (EKG) to rule out QTc prolongation; the patient may be referred to a cardiologist at the discretion of the principal investigator; patients with underlying cardiopulmonary dysfunction should be excluded from the study
-
Patients must have Zubrod performance status of 0-2
-
No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 5 years
-
Collection and submission of pre-treatment cytogenetic specimens must be completed within 28 days prior to registration on S0805
-
Collection and submission of pretreatment marrow and/or peripheral blood specimens for cellular and molecular studies, including verification of BCR/ABL status must be completed within 28 days prior to registration
-
Patients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures
-
Patients must not have prior history of known type I hypersensitivity or anaphylactic reactions to doxorubicin
-
Patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
-
At the time of patient registration, the treating institution's name and identification (ID) number must be provided to the Data Operations Center in Seattle in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered into the data base
-
MAINTENANCE/INTENSIFICATION:
-
Patient must have achieved CR or CRi within 2 courses of Induction/Consolidation Chemotherapy; patient must remain in CR or CRi until beginning Maintenance Chemotherapy and this must be re-documented by bone marrow and peripheral blood examination within 28 days prior to registration to Step 2
-
All treatment related toxicities must have resolved to =< grade 2
-
Patients must not have received allogeneic stem cell transplant
-
TRANSPLANT REGISTRATION:
-
Patients must have an available completely matched sibling donor or a 10/10 matched non-sibling donor
-
Patients must have allogeneic stem cell transplant arranged prior to registration to Step 3
-
Patients must have documented CR or CRi within 14 days prior to registration to Step 3
-
Patients must not be HIV + (human immunodeficiency virus); a negative HIV test must be obtained within 14 days prior to registration
-
POST TRANSPLANT/POST-MAINTENANCE SINGLE-AGENT DASATINIB THERAPY:
-
Patients must have reached day 100 post transplant or must have completed protocol maintenance/intensification (or must have been approved by the Study Chair after early removal from maintenance/intensification)
-
Patients must be in CR or CRi based on bone marrow and peripheral blood examination within 28 days prior to registration to Step 4
-
Patients must have recovered to =< grade 2 from all treatment related toxicity
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Treatment (chemotherapy, transplant, maintenance)
See Detailed Description |
Correlative studies Given IV
他の名前:
Given IV
他の名前:
Given PO
他の名前:
Given IV or PO
他の名前:
Given IV
他の名前:
Given IV
他の名前:
Given IV
他の名前:
Given SC
他の名前:
Given PO
他の名前:
Given IV
他の名前:
Given PO
他の名前:
Undergo TBI
他の名前:
Given IV
他の名前:
Given IT
他の名前:
Given IV or IT
他の名前:
Undergo allogeneic stem cell transplant
他の名前:
Undergo allogeneic stem cell transplant
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Relapse-free Survival (RFS) After Allogeneic Stem Cell Transplantation
時間枠:12 months
|
Will be estimated using the method of Kaplan-Meier. |
12 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Continuous Complete Remission (CCR) Rate
時間枠:18 months
|
Will be testing using an exact binomial test |
18 months
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall Survival (OS)
時間枠:From the date of initial registration on the study until death from any cause, assessed up to 5 years
|
OS will be estimated using the method of Kaplan-Meier. |
From the date of initial registration on the study until death from any cause, assessed up to 5 years
|
|
MRD as Assessed Using Real-time Quantitative Polymerase Chain Reaction and Flow Cytometry
時間枠:Up to 5 years
|
Correlation between the two measures of MRD measured on the same remission specimens will be examined using scatterplots and correlation analysis. The prognostic effect for relapse of each measure will be illustrated using cumulative incidence plots, and estimated using Cox regression models. This outcome will be reported as funding allows. |
Up to 5 years
|
協力者と研究者
捜査官
- 主任研究者:Farhad Ravandi-Kashani、SWOG Cancer Research Network
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (推定)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 新生物
- 免疫系疾患
- 感染症
- ウイルス病
- 組織型別の新生物
- 血液疾患
- DNAウイルス感染症
- リンパ疾患
- リンパ増殖性疾患
- 免疫増殖性疾患
- リンパ腫、非ホジキン
- リンパ腫、B細胞
- リンパ腫
- 白血病、リンパ
- 白血病
- エプスタイン-バーウイルス感染症
- ヘルペスウイルス感染症
- 腫瘍ウイルス感染症
- ヘミックおよびリンパ疾患
- 前駆細胞リンパ芽球性白血病-リンパ腫
- バーキットリンパ腫
- 前駆T細胞リンパ芽球性白血病-リンパ腫
- ペプチド
- アミノ酸、ペプチド、およびタンパク質
- タンパク質
- 硫黄化合物
- 有機化学物質
- 複素環化化合物、1リング
- 複素環化化合物
- 複素環化化合物、2リング
- 複素環化化合物、融合リング
- 調査手法
- 治療
- 外科的処置、手術
- チアゾール
- アゾール
- 核酸、ヌクレオチド、およびヌクレオシド
- 炭化水素
- 炭化水素、周期的
- 生物学的要因
- 炭水化物
- アルカロイド
- ポドフィロトキシン
- テトラヒドロノフタレン
- ナフタレン
- 多環芳香族炭化水素
- 炭化水素、芳香
- 多環式化合物
- グルコシド
- グリコシド
- 移植
- 酵素と補酵素
- インドール
- シチジン
- ピリミジンヌクレオシド
- ピリミジン
- 妊娠
- 妊娠
- ステロイド
- 融合リング化合物
- ステロイド、フッ素化
- ベンゼン誘導体
- スルホン酸
- 硫酸
- マクロライド
- ラクトン
- ホスホルアミドマスタード
- 窒素マスタード化合物
- マスタード化合物
- 炭化水素、ハロゲン化
- ホスホラミド
- 有機リン化合物
- ヌクレオシド
- ホルミルテトラヒドロフォレート
- テトラヒドロフォレート
- 葉酸
- 羽毛
- プテリジン
- 細胞間シグナル伝達ペプチドとタンパク質
- 妊娠症
- 妊娠した
- ヴィンカアルカロイド
- セコロガニントリプタミンアルカロイド
- インドールアルカロイド
- インドリジジン
- インドリジン
- アラビノヌクレオシド
- アミノプテリン
- アントラサイクリン
- ナフテセン
- アミノグリコシド
- コエンザイム
- 糖タンパク質
- グリココンジュゲート
- 放射線療法
- ダウノルビシン
- 細胞移植
- 細胞および組織ベースの治療
- 生物療法
- ベンゼンスルホン酸塩
- アリルスルホン酸塩
- アリールスルホン酸
- コロニー刺激因子
- 造血細胞成長因子
- サイトカイン
- プレドニゾロン
- 造血幹細胞移植
- ダサチニブ
- シロリムス
- デキサメタゾン
- メトトレキサート
- プレドニン
- シクロホスファミド
- シタラビン
- エトポシド
- ロイコボリン
- ドキソルビシン
- ビンクリスチン
- メチルプレドニゾロン
- タクロリムス
- ドベシル酸カルシウム
- 幹細胞移植
- デキサメタゾン21-リン酸
- 顆粒球コロニー刺激因子
- 全身照射
- Filgrastim
- デルタコルテン
- プレシリデン
- メルフォス
- Auricularum
- デキサメタゾン酢酸
- exifone
- Medrol Veriderm
- 末梢血幹細胞移植
その他の研究ID番号
- NCI-2009-00800
- U10CA032102 (米国 NIH グラント/契約)
- U10CA180888 (米国 NIH グラント/契約)
- NCI-2009-00800 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
- S0805 (その他の識別子:CTEP)
- CDR0000624250
- S0805
- S0805 (その他の識別子:SWOG)
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。